Tenofovir disoproxil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326978

CAS#: 201341-05-1 (free)

Description: Tenofovir disoproxil is an antiretroviral medication used to prevent and treat HIV/AIDS and to treat chronic hepatitis B. The active substance is tenofovir, while tenofovir disoproxil is a prodrug that is used because of its better absorption in the gut.

Chemical Structure

Tenofovir disoproxil
CAS# 201341-05-1 (free)

Theoretical Analysis

MedKoo Cat#: 326978
Name: Tenofovir disoproxil
CAS#: 201341-05-1 (free)
Chemical Formula: C19H30N5O10P
Exact Mass: 519.17
Molecular Weight: 519.448
Elemental Analysis: C, 43.93; H, 5.82; N, 13.48; O, 30.80; P, 5.96

Price and Availability

Size Price Availability Quantity
1g USD 150 2 weeks
2g USD 225 2 weeks
5g USD 450 2 weeks
10g USD 650 2 weeks
25g USD 950 2 weeks
50g USD 1650 2 weeks
Bulk inquiry

Related CAS #: 201341-05-1 (free)   202138-50-9 (fumarate)   147127-20-6 (Tenofovir)   206184-49-8 (hydrate)   379270-37-8 (alafenamide)   1571075-19-8 (aspartate)    

Synonym: Tenofovir disoproxil; Bis(POC)PMPA; PMPA prodrug; Viread.

IUPAC/Chemical Name: (R)-(((((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)bis(oxy))bis(methylene) diisopropyl bis(carbonate)


InChi Code: InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 201341-05-1 (Tenofovir disoproxil free form) 202138-50-9 (Tenofovir Disoproxil Fumarate) 1276030-80-8 (Tenofovir disoproxil maleate) 1453166-76-1 (Tenofovir disoproxil phosphate) 1637632-97-3 (Tenofovir disoproxil succinate) 1571075-19-8 (Tenofovir disoproxil aspartate)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 519.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016 Apr 29. pii: S0006-2952(16)30069-7. doi: 10.1016/j.bcp.2016.04.015. [Epub ahead of print] Review. PubMed PMID: 27133890.

2: Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 2016;15(2):265-73. doi: 10.1517/14740338.2016.1128412. Review. PubMed PMID: 26634852; PubMed Central PMCID: PMC4755800.

3: Kabbara WK, Ramadan WH. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J Infect Public Health. 2015 Sep-Oct;8(5):409-17. doi: 10.1016/j.jiph.2015.04.020. Epub 2015 May 19. Review. PubMed PMID: 26001757.

4: Deeks ED. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection. Drugs. 2014 Nov;74(17):2079-95. doi: 10.1007/s40265-014-0318-1. Review. PubMed PMID: 25352394.

5: Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015 Jan 15;60(2):275-8. doi: 10.1093/cid/ciu798. Epub 2014 Oct 13. Review. PubMed PMID: 25313254.

6: Manzardo C, Gatell JM. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment. AIDS Rev. 2014 Jan-Mar;16(1):35-42. Review. PubMed PMID: 24584107.

7: Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults. Drugs. 2014 Jan;74(1):75-97. doi: 10.1007/s40265-013-0158-4. Review. PubMed PMID: 24338165.

8: Lou L. Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. J Clin Transl Hepatol. 2013 Sep;1(1):33-8. doi: 10.14218/JCTH.2013.004XX. Epub 2013 Sep 15. Review. PubMed PMID: 26357604; PubMed Central PMCID: PMC4521268.

9: Plosker GL. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4. Review. PubMed PMID: 23444256.

10: Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Epub 2012 Nov 7. Review. PubMed PMID: 23136357.

11: Buti M, Homs M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):413-21. doi: 10.1586/egh.12.19. Review. PubMed PMID: 22928893.

12: Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs. 2012 May;21(5):695-715. doi: 10.1517/13543784.2012.667072. Epub 2012 Mar 7. Review. PubMed PMID: 22394224; PubMed Central PMCID: PMC3460694.

13: Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs. 2010 Dec 3;70(17):2315-38. doi: 10.2165/11203800-000000000-00000. Review. PubMed PMID: 21080746.

14: Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2010 Oct;8(10):1079-92. doi: 10.1586/eri.10.91. Review. PubMed PMID: 20954872.

15: Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010 Sep 1;51(5):496-505. doi: 10.1086/655681. Review. PubMed PMID: 20673002.

16: Jones J, Colquitt J, Shepherd J, Harris P, Cooper K. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. Health Technol Assess. 2010 May;14 Suppl 1:23-9. doi: 10.3310/hta14Suppl1/04. Review. PubMed PMID: 20507800.

17: Perry CM, Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs. 2009 Nov 12;69(16):2245-56. doi: 10.2165/10482940-000000000-00000. Review. PubMed PMID: 19852527.

18: Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med. 2009 Aug;10(7):397-406. doi: 10.1111/j.1468-1293.2009.00709.x. Epub 2009 May 12. Review. PubMed PMID: 19459986.

19: Stephan C. Experience with tenofovir disoproxil fumarate for antiretroviral therapy. Expert Opin Pharmacother. 2008 May;9(7):1197-209. doi: 10.1517/14656566.9.7.1197. Review. PubMed PMID: 18422476.

20: Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 2007 Feb;17(2):90-2, 99-104, C3. Review. PubMed PMID: 17323508.